Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 16, 2022

SELL
$22.67 - $28.01 $181,360 - $224,080
-8,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$24.13 - $32.63 $193,040 - $261,040
8,000 New
8,000 $221,000
Q3 2021

Nov 12, 2021

SELL
$29.97 - $36.66 $455,544 - $557,232
-15,200 Closed
0 $0
Q2 2021

Aug 06, 2021

BUY
$25.39 - $32.61 $385,928 - $495,672
15,200 New
15,200 $463,000
Q1 2021

May 14, 2021

SELL
$19.92 - $31.6 $284,856 - $451,880
-14,300 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$12.16 - $19.77 $47,424 - $77,103
-3,900 Reduced 21.43%
14,300 $281,000
Q3 2020

Nov 13, 2020

BUY
$11.25 - $14.75 $49,500 - $64,900
4,400 Added 31.88%
18,200 $232,000
Q2 2020

Aug 13, 2020

SELL
$10.69 - $16.49 $78,037 - $120,376
-7,300 Reduced 34.6%
13,800 $152,000
Q1 2020

May 11, 2020

SELL
$9.78 - $29.53 $72,372 - $218,522
-7,400 Reduced 25.96%
21,100 $306,000
Q4 2019

Feb 12, 2020

BUY
$20.93 - $35.1 $69,069 - $115,830
3,300 Added 13.1%
28,500 $756,000
Q3 2019

Nov 14, 2019

SELL
$22.08 - $47.08 $393,023 - $838,024
-17,800 Reduced 41.4%
25,200 $717,000
Q2 2019

Aug 20, 2019

BUY
$22.67 - $35.0 $974,810 - $1.51 Million
43,000 New
43,000 $1.2 Million
Q4 2018

Feb 14, 2019

SELL
$27.23 - $45.56 $909,482 - $1.52 Million
-33,400 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$37.57 - $50.34 $454,597 - $609,114
-12,100 Reduced 26.59%
33,400 $1.54 Million
Q1 2018

May 15, 2018

BUY
$28.83 - $41.01 $216,225 - $307,575
7,500 Added 19.74%
45,500 $1.35 Million
Q4 2017

Feb 14, 2018

BUY
$28.45 - $37.14 $113,800 - $148,560
4,000 Added 11.76%
38,000 $1.31 Million
Q3 2017

Nov 15, 2017

BUY
$24.01 - $36.2 $816,340 - $1.23 Million
34,000
34,000 $1.23 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.77B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.